Answers are grounded in this paper and cite their sources.
Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.
No takes yet. Share an insight, caveat, or question.
Lordick et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: